ClinicalTrials.gg

Carcinoma, Transitional Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 632 studies for Carcinoma, Transitional Cell across more than 10 countries. 180 are recruiting or about to start. 337 of them are mainly about Carcinoma, Transitional Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,163 studies for Carcinoma, Transitional Cell. How that becomes 633 here

This page counts the studies the registry files under Carcinoma, Transitional Cell, and those it files under no condition that list Carcinoma, Transitional Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,163Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −56List Carcinoma, Transitional Cell as a condition, but the registry did not file them under itMost often written as “Transitional Cell Carcinoma of the Bladder” (24), “Fallopian Tube Transitional Cell Carcinoma” (20), and “Ovarian Transitional Cell Carcinoma” (17). The registry filed them under other conditions only, most often Urinary Bladder Neoplasms (27) and Fallopian Tube Neoplasms (18).
  3. −474Match it another way54 name it in the title, 60 in a keyword, and 360 by a synonym or other text the search reads.
  4. 633The count on this page12 of them list Carcinoma, Transitional Cell in their own words; the registry filed them under no condition.

Status

Completed
203
Recruiting
147
Terminated
93
Active, not recruiting
79
Status unknown
51
Not yet recruiting
26

Phase

Phase 2
292
Phase 1
207
Phase 3
49
Early Phase 1
13
Phase 4
3

Where

United States
360
China
88
Spain
79
France
70
Canada
61
Italy
60

Who develops what

Add Carcinoma, Transitional Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 38 programs from 30 companies, 20 with this as their studies’ main aim; 14 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Astellas Pharma, AstraZeneca and Beijing Biotech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07815665 · Summit Therapeutics · Phase 3 · live · comparator · “Pembrolizumab” · registered Aug 2026
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Jun 2026
  • NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Dec 2025
  • NCT07218380 · Eli Lilly and Company · Phase 3 · live · background · “Pembrolizumab” · registered Oct 2025
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)99 studies
CisplatinRecent, repeated
Evidence
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Cisplatin” · registered Apr 2026
  • NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Cisplatin” · registered Aug 2025
  • NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Cisplatin/Carboplatin” · registered Sep 2024
  • NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Cisplatin” · registered Jun 2024
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed77 studies
GemcitabineRecent, repeated
Evidence
  • NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
  • NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
  • NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Sep 2024
  • NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed77 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07393542 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine and cisplatin / carboplatin” · registered Jan 2026
  • NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Dec 2025
  • NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Carboplatin” · registered Aug 2025
  • NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Cisplatin/Carboplatin” · registered Sep 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Carboplatin” · registered Aug 2023
Eli Lilly and Company16% of its industry studies77 studies
enfortumab vedotinRecent, repeated
Evidence
  • NCT07815665 · Summit Therapeutics · Phase 3 · live · background · “enfortumab vedotin (EV)” · registered Aug 2026
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2026
  • NCT06493552 · Vasgene Therapeutics, Inc · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2024
  • NCT05845814 · Merck & Co., Inc · Phase 2 · live · background · “EV” · registered Apr 2023
  • NCT03606174 · Bristol-Myers Squibb · Phase 2 · background · “Enfortumab vedotin” · registered Jul 2018
Astellas Pharma Inc65% of its industry studiesUS: Astellas Pharma Inc (FDA 2019)EU: Astellas Pharma Inc (EMA 2022)44 studies
NivolumabRecent, repeated
Evidence
  • NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT03633110 · Genocea Biosciences, Inc. · Phase 2 · background · “Nivolumab” · registered Aug 2018
  • NCT03311334 · Sumitomo Pharma Co., Ltd. · Phase 2 · background · “Nivolumab” · registered Oct 2017
  • NCT03241173 · Incyte Corporation · Phase 2 · background · “Nivolumab” · registered Aug 2017
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies
toripalimabRecent, repeated
Evidence
  • NCT07314723 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 2 · live · background · “Toripalimab Injection” · registered Dec 2025
  • NCT05302284 · RemeGen Co., Ltd. · Phase 3 · live · background · “Toripalimab” · registered Mar 2022
RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024)22 studies

15 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
UGN-104☆ Track1 live phase-3 study: NCT06774131UroGen Pharma Ltd.
izalontamab brengitecan☆ Track1 live phase-3 study: NCT06857175Sichuan Biokin Pharmaceutical Co., Ltd.
bulumtatug fuvedotin☆ Track1 live phase-3 study: NCT06592326Mabwell (Shanghai) Bioscience Co., Ltd.
toripalimabApproved: US 2023 · EU 2024☆ Track1 live phase-3 study: NCT06592326Mabwell (Shanghai) Bioscience Co., Ltd.
notiretatug rezetecan☆ Track1 live phase-3 study: NCT07393542Jiangsu HengRui Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 38 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT06405425 A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma — primary endpoint: Objective Response Rate (ORR) · 52 enrolled
  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors — primary endpoint: Objective response rate (ORR) · 52 enrolled
  • 31 Dec 2026 est.enfortumab vedotin · Astellas Pharma Inc · Phase 4 main aimNCT06862219 A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer — primary endpoint: Number of participants with Adverse events · 100 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Transitional Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 30 open · Antibody-drug conjugates (ADCs) 22 open · Tyrosine kinase inhibitors (TKIs) 8 open · Antimetabolites 5 open · Alkylating agents 3 open

Coming up

89studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger. 4 (3%) take children under 18. 2 (1%) are for women only and 1 (1%) for men only; 8 (5%) take healthy volunteers.

Recruiting studies that take each age, of 147
AgeWomenMen
103 (2%)3 (2%)
18139 (95%)137 (93%)
30142 (97%)141 (96%)
40143 (97%)142 (97%)
50145 (99%)144 (98%)
65146 (99%)145 (99%)
75144 (98%)143 (97%)
85129 (88%)128 (87%)

Across all 632 studies, recruiting or not: 5% stop at 75 or younger and <1% at 65; 4% take children; 1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Transitional Cell studies take

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo31–63 · 99 studies44 mo34–57 · 62 studies48 mo26–73 · 37 studies
Phase 1/264 mo51–224 · 47 studies——
Phase 257 mo35–102 · 119 studies—59 mo40–102 · 91 studies
Phase 356 mo24–111 · 28 studies——
Interventional, no phase58 mo23–… · 28 studies——
Observational56 mo27–89 · 61 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 632. Browse all 632 → or search them.